BACKGROUND:Intradialytic morbid events (IMEs) during haemodialysis (HD), including symptomatic hypotension, are related to ultrafiltration (UF)-induced hypovolaemia. Blood volume monitoring and automatic feedback control of the UF rate were developed to limit the extent of hypovolaemia during dialysis. The present study investigated the effect of blood volume (BV)-controlled UF on the incidence of HD treatments with IMEs. METHODS: This prospective randomised crossover study included hypotension-prone patients, characterised by occurrence of IMEs in at least 33% of HD treatments during a 6-week screening phase. These patients underwent 2 treatment phases, each lasting 6 weeks, in randomised order. Each patient served as their own control, treated with standard HD in one phase and with BV-controlled UF in the other phase. RESULTS:Thirty-four patients from 9 HD centres were enrolled; 26 could be included in the analysis population. In comparison with standard HD, BV-controlled UF reduced the percentage of HD sessions complicated by IME significantly from 40%+/-27% to 32%+/-25% (p=0.02). A lower frequency of HD sessions with IME could be observed in 46% of the patients. The frequency of treatments with symptomatic hypotension was reduced from 32%+/-23% in standard HD to 24%+/-21% with BV-controlled UF (p=0.04). Changes in blood pressure and heart rate from start to end of the HD session were not different between the 2 treatment modes. CONCLUSIONS: This crossover study showed improved intradialytic stability with BV-controlled UF, compared with standard HD.
RCT Entities:
BACKGROUND: Intradialytic morbid events (IMEs) during haemodialysis (HD), including symptomatic hypotension, are related to ultrafiltration (UF)-induced hypovolaemia. Blood volume monitoring and automatic feedback control of the UF rate were developed to limit the extent of hypovolaemia during dialysis. The present study investigated the effect of blood volume (BV)-controlled UF on the incidence of HD treatments with IMEs. METHODS: This prospective randomised crossover study included hypotension-prone patients, characterised by occurrence of IMEs in at least 33% of HD treatments during a 6-week screening phase. These patients underwent 2 treatment phases, each lasting 6 weeks, in randomised order. Each patient served as their own control, treated with standard HD in one phase and with BV-controlled UF in the other phase. RESULTS: Thirty-four patients from 9 HD centres were enrolled; 26 could be included in the analysis population. In comparison with standard HD, BV-controlled UF reduced the percentage of HD sessions complicated by IME significantly from 40%+/-27% to 32%+/-25% (p=0.02). A lower frequency of HD sessions with IME could be observed in 46% of the patients. The frequency of treatments with symptomatic hypotension was reduced from 32%+/-23% in standard HD to 24%+/-21% with BV-controlled UF (p=0.04). Changes in blood pressure and heart rate from start to end of the HD session were not different between the 2 treatment modes. CONCLUSIONS: This crossover study showed improved intradialytic stability with BV-controlled UF, compared with standard HD.
Authors: Kelvin C W Leung; Robert R Quinn; Pietro Ravani; Henry Duff; Jennifer M MacRae Journal: Clin J Am Soc Nephrol Date: 2017-10-10 Impact factor: 8.237
Authors: Manfred Hecking; Marlies Antlanger; Wolfgang Winnicki; Thomas Reiter; Johannes Werzowa; Michael Haidinger; Thomas Weichhart; Hans-Dietrich Polaschegg; Peter Josten; Isabella Exner; Katharina Lorenz-Turnheim; Manfred Eigner; Gernot Paul; Renate Klauser-Braun; Walter H Hörl; Gere Sunder-Plassmann; Marcus D Säemann Journal: Trials Date: 2012-06-08 Impact factor: 2.279
Authors: Christian Daugaard Peters; Krista Dybtved Kjaergaard; Jens Dam Jensen; Kent Lodberg Christensen; Charlotte Strandhave; Ida Noerager Tietze; Marija Kristina Novosel; Bo Martin Bibby; Bente Jespersen Journal: PLoS One Date: 2015-06-01 Impact factor: 3.240
Authors: Jennifer E Flythe; Matthew J Tugman; Julia H Narendra; Magdalene M Assimon; Quefeng Li; Yueting Wang; Steven M Brunelli; Alan L Hinderliter Journal: J Nephrol Date: 2020-09-25 Impact factor: 3.902
Authors: Marlies Antlanger; Manfred Hecking; Michael Haidinger; Johannes Werzowa; Johannes J Kovarik; Gernot Paul; Manfred Eigner; Diana Bonderman; Walter H Hörl; Marcus D Säemann Journal: BMC Nephrol Date: 2013-12-02 Impact factor: 2.388